Selected data models

You must log in to select data models for download or further analysis.

7 Search results.
Relevance Rating New first Old first

Serious Adverse Event (SAE)- Follow- Up Week 38 Mepolizumab HES NCT00086658 - Serious Adverse Event (SAE)- Additional/ Follow- Up Information Week 38

- 6/6/17 - 1 form, 1 itemgroup, 7 items, 1 language
Itemgroup: SAE
Study part: Serious Adverse Event (SAE)- Additional/ Follow- Up Information Week 38.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Pregnancy Follow- Up Form- Current Pregnancy Information Week 36 Mepolizumab HES NCT00086658 - Pregnancy Follow- Up Form- Current Pregnancy Information Week 36

- 7/15/17 - 1 form, 5 itemgroups, 39 items, 1 language
Itemgroups: FOLLOW-UP Pregnancy, INFANT INFORMATION, PREGNANCY INFORMATION, drug exposures pregnancy, information investigator
Study part: Pregnancy Follow- Up Form- Current Pregnancy Information Week 36/ Early Withdrawal Visit.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Pregnancy Follow-Up Form- Current Pregnancy Information Week 38 Mepolizumab HES NCT00086658 - Pregnancy Follow-Up Form- Current Pregnancy Information Week 38

- 6/6/17 - 1 form, 5 itemgroups, 39 items, 1 language
Itemgroups: FOLLOW-UP Pregnancy, INFANT INFORMATION, PREGNANCY INFORMATION, drug exposures pregnancy, information investigator
Study part: Pregnancy Follow-Up Form- Current Pregnancy Information Week 38.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Serious Adverse Event (SAE)- Additional/ Follow- Up Information Week 36 Mepolizumab HES NCT00086658 - Serious Adverse Event (SAE)- Additional/ Follow- Up Information Week 36

- 7/15/17 - 1 form, 1 itemgroup, 7 items, 1 language
Itemgroup: SAE
Study part: Serious Adverse Event (SAE)- Additional/ Follow- Up Information Week 36/ Early Withdrawal Visit.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Adverse events Safety follow-up visit Mepolizumab HES NCT00086658 - Adverse events Safety follow-up visit

- 7/15/17 - 1 form, 1 itemgroup, 1 item, 1 language
Itemgroup: Adverse Events
Study part: Adverse events Safety follow-up visit. A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Subject contact Safety follow-up visit Mepolizumab HES NCT00086658 - Subject contact Safety follow-up visit

- 7/15/17 - 1 form, 1 itemgroup, 4 items, 1 language
Itemgroup: CONTACT
Study part: Subject contact Safety follow-up visit.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Urine Pregnancy Test Prompt Safety follow-up visit Mepolizumab HES NCT00086658 - Urine Pregnancy Test Prompt Safety follow-up visit

- 7/15/17 - 1 form, 1 itemgroup, 2 items, 1 language
Itemgroup: Urine Pregnancy Test
Study part: Urine Pregnancy Test Prompt Safety follow-up visit.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial